Marengo Reports Late-Breaking Initial Phase 2 Clinical Results from Invikafusp Alfa Plus TRODELVY® and Unveils Partnered Novel IPN01203/STAR0501 STAR Program in Phase 1 at AACR 2026

B Encouraging Phase 2 clinical activity with confirmed complete responses observed in heavily pretreated metastatic breast cancer across both TNBC and HR+/HER2- subtypes First public…
posteditor
posteditor
Articles: 16137